Akiyama Kosuke, Karaki Masayuki, Kobayshi Ryuichi, Dobashi Hiroaki, Ishida Toshihiko, Mori Nozomu
Department of Otorhinolaryngology, Faculty of Medicine, Kagawa University, Kagawa 761-0793, Japan.
Int Arch Allergy Immunol. 2009;149(4):315-22. doi: 10.1159/000205577. Epub 2009 Mar 17.
Interleukin-16 (IL-16) is a cytokine that induces selective migration of CD4+ cells and participates in inflammatory diseases including allergic rhinitis. Histamine and prostaglandin D(2) are important chemical mediators of allergic inflammation, and antiallergic drugs are commonly used for the treatment of allergic rhinitis. It remains unknown whether treatment with the drugs affects IL-16.
We evaluated the variability of IL-16 and the effects of the antiallergic drugs fexofenadine (40 mg/kg/day) and ramatroban (30 mg/kg/day) on IL-16 in an OVA-sensitized BALB/c murine experimental allergic rhinitis model.
We measured the expression level of IL-16 protein in the mouse nasal septal mucosa by immunohistochemistry, and the serum level of IL-16 by ELISA. Several other parameters associated with allergic rhinitis (nasal symptoms, OVA-specific IgE, eosinophil and T cell infiltration) were also measured.
Local and systemic expressions of IL-16 were significantly increased in OVA-sensitized mice when compared to the nonsensitized group. Fexofenadine and ramatroban significantly inhibited the following OVA-induced allergic features when compared to the nontreated sensitized group: sneezing, nasal rubbing, eosinophil infiltration, IL-16 expressions in nasal tissue, and serum IL-16 level. Serum OVA-specific IgE and local T cell infiltration were reduced, but they did not reach significant values.
These results suggest that IL-16 was both systemically and locally upregulated in the murine allergic rhinitis model and that IL-16 changed in parallel to allergic state by treatment with the drugs.
白细胞介素-16(IL-16)是一种可诱导CD4+细胞选择性迁移并参与包括过敏性鼻炎在内的炎症性疾病的细胞因子。组胺和前列腺素D2是过敏性炎症的重要化学介质,抗过敏药物常用于治疗过敏性鼻炎。这些药物的治疗是否会影响IL-16仍不清楚。
我们在卵清蛋白(OVA)致敏的BALB/c小鼠实验性过敏性鼻炎模型中评估了IL-16的变异性以及抗过敏药物非索非那定(40毫克/千克/天)和雷马曲班(30毫克/千克/天)对IL-16的影响。
我们通过免疫组织化学法检测小鼠鼻中隔黏膜中IL-16蛋白的表达水平,并通过酶联免疫吸附测定法检测血清中IL-16的水平。还测量了与过敏性鼻炎相关的其他几个参数(鼻部症状、OVA特异性免疫球蛋白E、嗜酸性粒细胞和T细胞浸润)。
与未致敏组相比,OVA致敏小鼠中IL-16的局部和全身表达均显著增加。与未治疗的致敏组相比,非索非那定和雷马曲班显著抑制了以下OVA诱导的过敏特征:打喷嚏、擦鼻、嗜酸性粒细胞浸润、鼻组织中IL-16的表达以及血清IL-16水平。血清OVA特异性免疫球蛋白E和局部T细胞浸润减少,但未达到显著水平。
这些结果表明,在小鼠过敏性鼻炎模型中,IL-16在全身和局部均上调,并且通过药物治疗,IL-16与过敏状态平行变化。